Abeona Therapeutics (NASDAQ:ABEO) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Several other equities research analysts also recently weighed in on ABEO. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 16th. Zacks Investment Research downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Thursday, August 24th. Royal Bank Of Canada initiated coverage on Abeona Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price target on the stock. Finally, Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.10.

Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down $0.75 during midday trading on Friday, reaching $16.55. The company’s stock had a trading volume of 638,391 shares, compared to its average volume of 766,060. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.22 million. equities analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $122,000. Rhumbline Advisers acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $190,000. Bank of New York Mellon Corp boosted its position in shares of Abeona Therapeutics by 125.8% during the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $264,000. Finally, California State Teachers Retirement System acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $275,000. 41.95% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/abeona-therapeutics-abeo-rating-lowered-to-sell-at-valuengine/1741617.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.